Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eton Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eton Pharmaceuticals's regulatory disclosures and financial reporting.
ETON insider filed a Form 144 to sell 25,000 shares. The filing lists a stock option exercise for 25,000 common shares to be sold for cash on 06/23/2026. The filing also reports a prior sale of 3,117 shares on 06/02/2026 for $84,041.00.
Eton Pharmaceuticals director Jennifer McKie Adams reported an option exercise paired with an open-market sale of common stock. She exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share, then sold 50,000 shares in open-market transactions at a weighted average price of $32.4759 per share.
The sale was executed in multiple trades at prices ranging from $32.10 to $32.71, and the option grant, which vested quarterly, was fully vested by February 7, 2023. Following these transactions, Adams reported no remaining holdings of common stock or employee stock options.
Eton Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 9, 2026. Stockholders elected Jenn Adams and Charles J. Casamento to the board for three-year terms and ratified Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026.
Eton Pharmaceuticals, Inc. Chief Financial Officer Judith M. Matthews filed an initial Form 3 disclosing beneficial ownership of an employee stock option linked to 37,000 shares of common stock at an exercise price of $26.05 per share, expiring on April 12, 2036.
According to the disclosure, these employee stock options will vest in four equal installments on April 13 of 2027, 2028, 2029 and 2030, and are held directly by Matthews.
Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported open-market sales of a total of 120,000 shares of common stock on May 28, 2026. The transactions were executed at weighted-average prices, with individual trade prices ranging from $31.59 to $32.55 per share.
Following these sales, Brynjelsen directly held about 833,694 shares of Eton common stock. The filing notes that full details of the number of shares sold at each separate price are available upon request from the company, the SEC staff, or any security holder.
The Charles Schwab Corporation files a Form 144 notice proposing sale of 120,000 common shares for an aggregate amount of $3,888,000.00. Shares outstanding were 27,392,358 as of 05/28/2026, and the securities are listed on NASDAQ. The filing lists prior issuances and purchases dated 05/17/2017, 08/13/2019, 06/03/2021, and 08/21/2021.
Eton Pharmaceuticals Chief Business Officer David Krempa exercised stock options and sold shares in several open-market trades. On May 22–27, 2026, he exercised options to acquire 87,794 shares of common stock at exercise prices of $1.37–$3.58 per share and sold 100,000 shares in open-market transactions at weighted average prices in the low-to-mid $30s, as detailed in the filing.
Following these transactions, he holds 25,249 shares of Eton common stock directly and retains 118,406 employee stock options, according to the reported post-transaction balances.
ETON Rule 144 disclosure: This excerpt lists transferrable equity granted by the issuer and related quantities and dates. It shows multiple equity items including RSUs and Options with specific grant or event dates and share counts, and references Nasdaq as the market.